Literature DB >> 19294484

Rapid response and sustained remission by rituximab in four cases of plasma-exchange-failed acute thrombotic thrombocytopenic purpura.

Laura Scaramucci1, Pasquale Niscola2, Roberto Palumbo3, Marco Giovannini1, Micaela Ales1, Andrea Tendas1, Luca Cupelli1, Giuseppina Natale1, Teresa Dentamaro1, Alessio Pio Perrotti1, Paolo de Fabritiis1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19294484     DOI： 10.1007/s12185-009-0274-9

Source DB:  PubMed          Journal:  Int J Hematol        ISSN： 0925-5710            Impact factor:   2.490


× No keyword cloud information.
  9 in total

Review 1.  Rituximab provided long-term remission in a patient with refractory relapsing thrombotic thrombocytopenic purpura.

Authors:  Satoru Kosugi; Masanori Matsumoto; Yasushi Ohtani; Hironori Take; Hiromichi Ishizashi; Yoshihiro Fujimura; Jun Kuyama
Journal:  Int J Hematol       Date:  2005-06       Impact factor: 2.490

Review 2.  Targeting the inhibitor of ADAMTS13 in thrombotic thrombocytopenic purpura.

Authors:  Spero R Cataland; Haifeng M Wu
Journal:  Expert Opin Pharmacother       Date:  2007-03       Impact factor: 3.889

3.  Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS-13.

Authors:  Marie Scully; Hannah Cohen; Jamie Cavenagh; Sylvia Benjamin; Richard Starke; Sally Killick; Ian Mackie; Samuel J Machin
Journal:  Br J Haematol       Date:  2007-02       Impact factor: 6.998

Review 4.  Rituximab for acute plasma-refractory thrombotic thrombocytopenic purpura. A case report and concise review of the literature.

Authors:  Axel Rüfer; Doreen Brodmann; Michael Gregor; Johanna A Kremer Hovinga; Bernhard Lämmle; Walter A Wuillemin
Journal:  Swiss Med Wkly       Date:  2007-09-22       Impact factor: 2.193

Review 5.  Current management of thrombotic thrombocytopenic purpura.

Authors:  Johanna A Kremer Hovinga; Sara C Meyer
Journal:  Curr Opin Hematol       Date:  2008-09       Impact factor: 3.284

Review 6.  Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura.

Authors:  J Evan Sadler
Journal:  Blood       Date:  2008-07-01       Impact factor: 22.113

7.  Successful treatment of severe thrombotic thrombocytopenic purpura with the monoclonal antibody rituximab.

Authors:  Jens Chemnitz; Andreas Draube; Christof Scheid; Peter Staib; Armin Schulz; Volker Diehl; Dietmar Söhngen
Journal:  Am J Hematol       Date:  2002-10       Impact factor: 10.047

8.  Rituximab therapy for refractory thrombotic thrombocytopenic purpura.

Authors:  Lorence A Gutterman; Bruce Kloster; Han-Mou Tsai
Journal:  Blood Cells Mol Dis       Date:  2002 May-Jun       Impact factor: 3.039

Review 9.  Rituximab as an adjunct to plasma exchange in TTP: a report of 12 cases and review of literature.

Authors:  Sushama Jasti; Thomas Coyle; Teresa Gentile; Lawrence Rosales; Bernard Poiesz
Journal:  J Clin Apher       Date:  2008       Impact factor: 2.821
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.